These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33246442)

  • 1. Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes.
    Fernández-Simón E; Lleixà C; Suarez-Calvet X; Diaz-Manera J; Illa I; Gallardo E; de Luna N
    BMC Musculoskelet Disord; 2020 Nov; 21(1):784. PubMed ID: 33246442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of thrombospondin 1 in macrophage inflammation in dysferlin myopathy.
    De Luna N; Gallardo E; Sonnet C; Chazaud B; Dominguez-Perles R; Suarez-Calvet X; Gherardi RK; Illa I
    J Neuropathol Exp Neurol; 2010 Jun; 69(6):643-53. PubMed ID: 20467328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of dysferlin alters myogenin expression and delays human muscle differentiation "in vitro".
    de Luna N; Gallardo E; Soriano M; Dominguez-Perles R; de la Torre C; Rojas-García R; García-Verdugo JM; Illa I
    J Biol Chem; 2006 Jun; 281(25):17092-17098. PubMed ID: 16608842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors increase missense mutated dysferlin in patients with muscular dystrophy.
    Azakir BA; Erne B; Di Fulvio S; Stirnimann G; Sinnreich M
    Sci Transl Med; 2014 Aug; 6(250):250ra112. PubMed ID: 25143362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The absence of dysferlin induces the expression of functional connexin-based hemichannels in human myotubes.
    Cea LA; Bevilacqua JA; Arriagada C; Cárdenas AM; Bigot A; Mouly V; Sáez JC; Caviedes P
    BMC Cell Biol; 2016 May; 17 Suppl 1(Suppl 1):15. PubMed ID: 27229680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of Hemichannels Normalizes the Differentiation Fate of Myoblasts and Features of Skeletal Muscles from Dysferlin-Deficient Mice.
    Cea LA; Fernández G; Arias-Bravo G; Castillo-Ruiz M; Escamilla R; Brañes MC; Sáez JC
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysferlin function in skeletal muscle: Possible pathological mechanisms and therapeutical targets in dysferlinopathies.
    Cárdenas AM; González-Jamett AM; Cea LA; Bevilacqua JA; Caviedes P
    Exp Neurol; 2016 Sep; 283(Pt A):246-54. PubMed ID: 27349407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of oxidative stress, nuclear factor kappa B and the ubiquitin proteasomal pathway in dysferlinopathy.
    Rajakumar D; Senguttuvan S; Alexander M; Oommen A
    Life Sci; 2014 Jul; 108(1):54-61. PubMed ID: 24846833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with galectin-1 improves myogenic potential and membrane repair in dysferlin-deficient models.
    Vallecillo-Zúniga ML; Rathgeber MF; Poulson PD; Hayes S; Luddington JS; Gill HN; Teynor M; Kartchner BC; Valdoz J; Stowell C; Markham AR; Arthur C; Stowell S; Van Ry PM
    PLoS One; 2020; 15(9):e0238441. PubMed ID: 32881965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1α,25(OH)(2)-Vitamin D3 increases dysferlin expression in vitro and in a human clinical trial.
    De Luna N; Díaz-Manera J; Paradas C; Iturriaga C; Rojas-García R; Araque J; Genebriera M; Gich I; Illa I; Gallardo E
    Mol Ther; 2012 Oct; 20(10):1988-97. PubMed ID: 22910291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy.
    Chiu YH; Hornsey MA; Klinge L; Jørgensen LH; Laval SH; Charlton R; Barresi R; Straub V; Lochmüller H; Bushby K
    Hum Mol Genet; 2009 Jun; 18(11):1976-89. PubMed ID: 19286669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A promotive effect for halofuginone on membrane repair and synaptotagmin-7 levels in muscle cells of dysferlin-null mice.
    Barzilai-Tutsch H; Dewulf M; Lamaze C; Butler Browne G; Pines M; Halevy O
    Hum Mol Genet; 2018 Aug; 27(16):2817-2829. PubMed ID: 29771357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPK Complex Activation Promotes Sarcolemmal Repair in Dysferlinopathy.
    Ono H; Suzuki N; Kanno SI; Kawahara G; Izumi R; Takahashi T; Kitajima Y; Osana S; Nakamura N; Akiyama T; Ikeda K; Shijo T; Mitsuzawa S; Nagatomi R; Araki N; Yasui A; Warita H; Hayashi YK; Miyake K; Aoki M
    Mol Ther; 2020 Apr; 28(4):1133-1153. PubMed ID: 32087766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GREG cells, a dysferlin-deficient myogenic mouse cell line.
    Humphrey GW; Mekhedov E; Blank PS; de Morree A; Pekkurnaz G; Nagaraju K; Zimmerberg J
    Exp Cell Res; 2012 Jan; 318(2):127-35. PubMed ID: 22020321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysferlin-deficient immortalized human myoblasts and myotubes as a useful tool to study dysferlinopathy.
    Philippi S; Bigot A; Marg A; Mouly V; Spuler S; Zacharias U
    PLoS Curr; 2012 Feb; 4():RRN1298. PubMed ID: 22367358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle atrophy, ubiquitin-proteasome, and autophagic pathways in dysferlinopathy.
    Fanin M; Nascimbeni AC; Angelini C
    Muscle Nerve; 2014 Sep; 50(3):340-7. PubMed ID: 24395438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective membrane repair in dysferlin-deficient muscular dystrophy.
    Bansal D; Miyake K; Vogel SS; Groh S; Chen CC; Williamson R; McNeil PL; Campbell KP
    Nature; 2003 May; 423(6936):168-72. PubMed ID: 12736685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response.
    Cohen TV; Cohen JE; Partridge TA
    Neuromuscul Disord; 2012 Jul; 22(7):648-58. PubMed ID: 22560623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysferlin interacts with calsequestrin-1, myomesin-2 and dynein in human skeletal muscle.
    Flix B; de la Torre C; Castillo J; Casal C; Illa I; Gallardo E
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1927-38. PubMed ID: 23792176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The earliest pathologic alterations in dysferlinopathy.
    Selcen D; Stilling G; Engel AG
    Neurology; 2001 Jun; 56(11):1472-81. PubMed ID: 11402103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.